Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00029107
Recruitment Status :
First Posted : January 7, 2002
Results First Posted : April 3, 2012
Last Update Posted : April 16, 2012
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Michael C Sneller, MD, National Institutes of Health Clinical Center (CC)
Between June 2002 and April 2010, a total of 24 patients were enrolled in the study. Twelve patients randomized to the rituximab group and 12 patients to the control group.
A total of 47 patients were screened for randomization into this study. Eighteen patients did not meet one or more of the above eligibility criteria. Five eligible patients elected not to enroll in the study because of concerns about potential rituximab toxicity. The remaining 24 patients were enrolled in the study and underwent randomization
Patients receive treatment with fou...
Receives standard therapy. After 6 ...
Patients receive treatment with four weekly infusions of rituximab immediately following randomization.
Receives standard therapy. After 6 months, they are eligibile to cross over and receive four weekly infusions of rituximab.